



## **PRESS RELEASE**

**Published:** 19-09-2018

### **Ziccum AB (publ) announces first day of subscription in new share issue, ahead of planned listing on Spotlight**

**STOCKHOLM, SWEDEN – 19 September, 2018. Ziccum AB (publ) has already been approved for listing on Stockholm stock market Spotlight, provided the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue begins today and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.**

The Investment Memorandum, Teaser and Application Form for the issue is available on the companies' respective websites, [www.ziccum.com](http://www.ziccum.com), [www.aqurat.se](http://www.aqurat.se) and [www.spotlightstockmarket.com](http://www.spotlightstockmarket.com).

#### **Ziccum: Offering and opportunity**

Through its patented technology LaminarPace, Ziccum is the only company in the world able to dry liquid biological vaccines and therapies *at room temperature*, proven to be a significantly gentler, more effective technique than present alternatives.

By being able to do this, Ziccum's vision is enabling the delivery of safe and effective dry powder drugs to any environment in the world. So minimizing the need for costly and impractical global 'cold chains', or refrigeration and freezer transport and storage chains.

The technology has been validated during many years and in a series of studies and can be applied to both existing drugs, and new drugs in development.

> 95% of all traditional drugs (so-called small molecules) are formulated in dry form, such as tablets or powders. Making them cheap and safe to transport and handle. But for biological therapies, the corresponding figure is scarcely 20%. This is largely due to how sensitive biological therapies are to extreme temperatures—thus ruling out the use of conventional drying therapies like freeze or spray drying.

Ziccum's business model is based on the sale of licenses to formulations generated as the result of LaminarPace. Ziccum creates value for its customers by offering a more stable, dry powder form of their own product—with a longer shelf-life and easier storage and transportation requirements. This gives customers a competitive advantage, cost savings and the opportunity to address more and bigger markets, as well as being protected by new patents that will protect this competitive advantage over time.

Ziccum was founded as a spin-out from Inhalation Sciences AB, which was successfully listed on Spotlight (formerly Aktietorget) in September 2017.

## **CEO Göran Conradson comments:**

"Ziccum is a company in the early commercialization phase, but with a proven technology and methodology that has been developed over years and validated in a number of projects. We're targeting the biological therapies market. It's making strong advances, but its history and needs show a sector that has been crying out to be able to formulate and manufacture its products in a dry form, but has been lacking a technical solution.

"Listing Ziccum on Spotlight is an exciting challenge. A listing enables us to drive our commercialization plans further, with more resources and speed to help LaminarPace reach its potential."

## **Listing issue in brief**

- Subscription period: September 19 - October 3, 2018
- Subscription price: 5.26 SEK per unit, which corresponds to 5.26 SEK per share. The warrants of series TO 1 are issued free of charge.
- Emissions volume: maximum 3,000,000 units. The lowest limit for the execution of the issue is 1 901 141 units, corresponding to 10 MSEK.
- Unit: One unit consists of one share and a non-subscription warrants series of TO1. Two warrants of series TO 1 entitles you to subscribe for a new share at the closing price 10 SEK during the period 1-31 December 2019.
- Minimum subscription item: Minimum subscription item is 1 unit for those subscribing with preferential rights and at least 1,000 units for those who subscribe without preferential rights.
- Pre-money valuation: Approximately 15.8 MSEK

## **Investor events**

In connection with the rights issue, Ziccum will participate in information meetings to inform people about the company's business and future plans. Currently, the following events are booked (more may be added):

- Göteborg, aktiedagen 24 september
- Stockholm, investerarkvällen 25 september
- Malmö, aktiedagen 26 september

## **Advisors**

Fredersen Advokatbyrå AB acts as legal adviser in connection with the issue. Aqurat Fondkommission AB acts as the issuer.

## **For questions about registration and subscription:**

Aqurat Fondkommission AB  
Tel: 08 - 684 05 800  
E-mail: [info@aqurat.se](mailto:info@aqurat.se)  
[www.aqurat.se](http://www.aqurat.se)

## **For more information on Ziccum, please contact:**

Göran Conradson: CEO  
Email: [conradson@ziccum.com](mailto:conradson@ziccum.com)  
Mob: +46 709 61 55 99

**About Ziccum AB (publ)**

Ziccum develops new formulations of biological drugs. The company's patented technology, LaminarPace, develops dry formulations of products that are currently only available in liquid form. Through this Ziccum can open up new markets, create new patents and generate revenues from new license sales.